Healthcare Industry News: BioMarin Pharmaceutical
News Release - March 31, 2022
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory AffairsHARRISON, N.Y., March 31, 2022 -- (Healthcare Sales & Marketing Network) -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs.
Dr. Capiaux has a long-standing career in the biotechnology and pharmaceutical industry, holding several senior level positions at notable companies. Dr. Capiaux joined Sapience from Ultragenyx Pharmaceutical, where she served as a Senior Director and led multiple programs for rare genetic disorders including the enzyme replacement therapy Mepsevii™ for mucopolysaccharidosis 7 (MPS 7) and Dojolvi® for long-chain fatty acid oxidation disorders (LC-FAOD). Previously, she held positions of increasing responsibility at BioMarin Pharmaceutical, where she led the program for Vimizim® for (MPS 4A) and various other small molecule and biologic programs. Dr. Capiaux holds a B.A. in biochemistry from California State University Fresno and a Ph.D. in Pharmacology from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center.
Dr. Capiaux added, "The potential of Sapience's approach to target undruggable intracellular interactions is immense, and I am thrilled to join the leadership team and help deliver its potentially life-changing pipeline to patients with cancer."
About Sapience Therapeutics
Sapience Therapeutics, Inc. is a privately held, clinical stage biotechnology company focused on discovering and developing peptide therapeutics for major unmet medical needs, particularly high mortality cancers. Sapience's approach holds potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead program, ST101, is a peptide antagonist of C/EBPβ that has demonstrated clinical proof-of-concept in Phase 1 with a confirmed partial response (PR). ST101 is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com and engage with us on LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.
Source: Sapience Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.